News Release Details
News Release Details
Jaguar Health Shares Replay Link for March 14, 2022, Investor Webcast
Click here to access webcast replay
Core 2022 development initiatives:
- Ongoing operation of Company's
OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) - Initiation and completion in 2H 2022 of investigator-initiated proof-of-concept study of crofelemer for short bowel syndrome with intestinal failure (SBS-IF)
FDA conditional approval in
Fourth quarter 2021 Mytesi net revenue was approximately
About
For more information about
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
phodge@jaguar.health
Jaguar-JAGX
###
SOURCE:
accesswire.com
https://www.accesswire.com/692985/Jaguar-Health-Shares-Replay-Link-for-March-14-2022-Investor-Webcast